Justice Samuel Alito on Monday temporarily halted a lower court ruling that would have restricted access to mifepristone, one of two drugs used in medication abortion. The pause will last for one week as the Supreme Court considers the broader case.
The original ruling from the 5th U.S. Circuit Court of Appeals would have required patients to have an in-person doctor visit before receiving prescriptions for mifepristone. Alito's action temporarily restores expanded access to the drug, reversing what would have been a significant reduction in how the medication can be dispensed.
Legal observers note that the one-week pause does not indicate how the full court will ultimately rule on the merits of the case.
What the Right Is Saying
Conservatives expressed concern about the ruling being paused rather than upheld. Groups including Students for Life of America and the Family Research Council have argued that medication abortion drugs require greater medical oversight to ensure patient safety.
"The FDA's original approval process for these drugs did not include adequate safeguards," said Kristan Hawkins, president of Students for Life of America. "Patients deserve to know what they are taking and to receive proper medical supervision."
Sen. James Lankford of Oklahoma, who has been active on abortion-related legislation, has previously stated that Congress should act to restrict certain abortion medications. Other Republican senators have called for clearer labeling requirements and additional clinical studies before expanded access continues.
Some legal conservatives noted that a one-week pause is procedural rather than substantive. "This is simply how the court manages its docket," said Jonathan Meyer, a former Justice Department official now at the Heritage Foundation. "It tells us nothing about where the justices will land."
What the Left Is Saying
Abortion rights advocates welcomed Alito's temporary order as a necessary reprieve for patients who rely on medication abortion. Groups including Planned Parenthood and the American Civil Liberties Union have argued that restrictions on mifepristone create unnecessary barriers to care, particularly in states where abortion services are limited.
"People should be able to access medication abortion without jumping through bureaucratic hoops," said Gillian Richards, a spokesperson for NARAL Pro-Choice America. "Today's order provides temporary relief while the courts continue their work."
Senate Democrats have largely supported expanded mifepristone access. Sen. Patty Murray of Washington state, who has championed reproductive health issues, has previously argued that medication abortion is safe and effective when prescribed appropriately.
Reproductive health researchers note that medication abortion accounts for more than half of all abortions performed in the United States since the Supreme Court's 2022 Dobbs decision overturned Roe v. Wade.
What the Numbers Show
According to data from the Guttmacher Institute, medication abortion accounted for approximately 54 percent of all abortions in the United States in 2023, up from 53 percent in 2022 and 39 percent in 2017. The increase coincides with state-level abortion restrictions enacted after the Dobbs decision.
Mifepristone was first approved by the FDA in 2000 for use up to seven weeks of pregnancy. In 2016, the agency expanded approval to 10 weeks. During the COVID-19 pandemic, the FDA temporarily allowed mail-order dispensing of the drug and later made that change permanent.
The 5th Circuit ruling at issue would have reversed these expansions, requiring mifepristone to be dispensed only in person and reverting to the original seven-week window. The court had given the government until May 10 to comply with its order.
According to FDA data, more than 6 million women of reproductive age live in states where abortion is now effectively banned or severely restricted following Dobbs.
The Bottom Line
Alito's one-week pause buys time for both sides while the Supreme Court decides whether to take up the case on its merits. Legal experts expect a full ruling could come before the court's term ends in June, though such decisions typically take months of deliberation.
The case touches on several significant legal questions: FDA regulatory authority over drug approvals, the interplay between federal and state regulation of medications, and how courts should handle challenges to agency science-based decisions.
What happens next depends largely on whether a majority of justices agree to hear arguments. If they decline, the 5th Circuit ruling would take effect immediately, restricting mifepristone access in Texas and several other states under that court's jurisdiction. Watch for any additional procedural orders from the Supreme Court this week.